Literature DB >> 12234859

In vitro activities of newer quinolones against bacteroides group organisms.

D R Snydman1, N V Jacobus, L A McDermott, R Ruthazer, E Goldstein, S Finegold, L Harrell, D W Hecht, S Jenkins, C Pierson, R Venezia, J Rihs, S L Gorbach.   

Abstract

The activities of BMS-284576, clinafloxacin, moxifloxacin, sitafloxacin, trovafloxacin, imipenem, cefoxitin, and clindamycin against 589 Bacteroides fragilis group isolates were determined. The activity of BMS-284576 was comparable to that of trovafloxacin. Sitafloxacin and clinafloxacin were the most active quinolones, and moxifloxacin was the least active. B. fragilis was the most susceptible of the species, and Bacteroides vulgatus was the most resistant. Association of specific antibiotic resistance with Bacteroides species was noted for all quinolones.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234859      PMCID： PMC128763          DOI： 10.1128/AAC.46.10.3276-3279.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Authors:  D R Snydman; L McDermott; G J Cuchural; D W Hecht; P B Iannini; L J Harrell; S G Jenkins; J P O'Keefe; C L Pierson; J D Rihs; V L Yu; S M Finegold; S L Gorbach
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

7.  National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Clin Infect Dis       Date:  2002-09-01       Impact factor: 9.079

Review 8.  Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.

Authors:  E J Goldstein
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

9.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191
View more
  11 in total

1.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

3.  Efficacy of moxifloxacin monotherapy versusgatifloxacin monotherapy, piperacillin-tazobactam combination therapy, and lindamycin plus gentamicin combination therapy: An experimental study in a rat model of intra-abdominal sepsis induced by fluoroquinolone-resistant Bacteroides fragilis.

Authors:  Ronald L Cisneros; Andrew B Onderdonk
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

4.  Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; Kelly A Sprandel; Keith A Rodvold; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 6.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

7.  In vitro activities of tigecycline against the Bacteroides fragilis group.

Authors:  N V Jacobus; L A McDermott; R Ruthazer; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

8.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 9.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.